Dr. Brian G.M. Durie focuses on early disease management including criteria for diagnosis and best treatment options. Patients are increasingly diagnosed early and must be certain if decisive first therapy is appropriate or if observation is recommended. With the introduction of new therapies, there are many options to be reviewed and considered for patients in each risk group, including assessment for age and comorbidities. Current best treatment guidelines are discussed. 

DOWNLOAD SLIDES


We thank our sponsors for supporting this educational program: 
Celgene, and Takeda Oncology

Previous Post
What new information is there about myeloma drugs in clinical trials?
Next Post
Can CAR T-cell therapies be used earlier in the treatment of multiple myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.